AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Avacta Group PLC (AIM:AVCT) AffyXell milestone and increased equity stake
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Avacta Group PLC (AIM:AVCT) Poster presented at the AACR available to download
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) AffyXell partners with Biocytogen and KNTSC
AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center
4d Pharma PLC (AIM:DDDD) MRx0518 + Keytruda – Primary endpoint met in RCC
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
4d Pharma PLC (AIM: DDDD) Participation in Chardan Microbiome Summit
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
4d Pharma PLC (AIM: DDDD) Parkinson’s trial receives FDA IND clearance
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
4d Pharma PLC (AIM: DDDD) Restatement of Interim Results to June 30, 2021
4D pharma to Restate Unaudited Interim Financial Statements for the Six-Month Period Ended June 30, 2021 to Correct Accounting for Warrants
Avacta Group PLC (AVCT.L) Dose escalation in the phase I trial of AVA6000
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AVCT.L) Second pre|CISION Pro-drug Candidate Selected
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM
